The laboratory of Eduard Batlle, in collaboration with the Group of Azucena Salas at the Hospital Clinic of Barcelona, will explore the therapeutic potencial of intestinal stem cells.
The analysis of the epigenome of more than 100 patients identifies the cells that give rise to the disease, opening avenues to improved diagnosis
The study reveals more than one million epigenetic alterations, an unexpected finding indicating that cancer cells undergo extensive epigenetic reprogramming.
Start-up of a 5-year European project that seeks to tackle the challenge of developing a type of oral medicine that can pass through the digestive tract intact.
If successful, the TRANS-INT consortium will contribute to improving the treatment of chronic diseases, such as diabetes, and pain.
The researcher Ernest Giralt, an expert in the design of peptides and proteins with the capacity to cross biological barriers, forms part of a macro-consortium that involves 17 institutions in Europe.
Twenty-four students in their first year of baccalaureate are selected to participate in a course that will allow them to deepen their knowledge of life sciences.
More than 40 scientists from 11 centres bear out the strength of the science performed with the fruit fly in Spain
From this international platform, Guinovart will work “to further scientists and science, especially in those places of the world with the most unfavorable conditions”.
The institute signs a 5-year scientific collaboration agreement with the RIKEN Center for Developmental Biology in Japan
Iproteos is developing a drug to treat the symptoms of schizophrenia and has already obtained its first results in animals.
The company has completed a first funding round, achieving more than 100,000 euros, and anticipates a second round of funding from business angels this autumn.
Set up in 2011 as a biotech spin-off from the Institute for Research in Biomedicine and the University of Barcelona, Iproteos has received support from the Ministry of Enterprise and Labour through the Evaluation Units managed by ACC1Ó.
Researchers headed by Maria Macias an ICREA researcher at the Institute for Research in Biomedicine (IRB Barcelona) and Joan Massagué, a Howard Hughes Medical Institute investigator at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York, have identified a new molecular mechanism that plays a crucial role in the control of the activation of certain genes associated with cancer.
Through detailed structural and biochemical studies, the researchers identified a key domain present in a family of proteins called Smads, whose binding determines whether the transcription of genes controlled by the TGF-beta and BMP signaling cascades will be bound by activators or labeled for...
The Nek9 protein is required for chromosomes to separate into two identical groups.
Nek9 exerts its action between two molecules of interest for the pharmaceutical industry as anti-tumoral agents, and for which inhibitors are already in advanced stages of clinical trials. Nek9 could be added to the list of candidates.